Results 201 to 210 of about 69,107 (331)

An experimental medicine protocol for exploring the haemodynamic effects of dual agonism at the glucagon‐like peptide‐1 and glucagon receptor in healthy subjects

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 579-588, February 2026.
Aims Glucagon‐like peptide‐1 (GLP‐1) and glucagon dual receptor agonists are in clinical development for a range of metabolic conditions, including type 2 diabetes and obesity. The cardiovascular actions at these receptors are well studied, but less is known about their combination.
James Goodman, Victoria E. Parker, Carmel M. McEniery, Giovanni Di Stefano, Annette Hubsch, Evangelia Vamvaka, Jo Helmy, Fotini Kaloyirou, Navazh Jalaludeen, Peter Barker, Lutz Jermutus, Joseph Cheriyan, Philip Ambery, Ian B. Wilkinson   +13 more
wiley   +1 more source

Health economic evaluation of dipeptidyl peptidase-4 inhibitors

Indian Journal of Endocrinology and Metabolism, 2011
Vishvas Garg
doaj   +1 more source

Increased dipeptidyl peptidase 4 in patients with concomitant transthyretin cardiac amyloidosis and severe aortic stenosis. [PDF]

Int J Cardiol Heart Vasc
Holt MF, Michelsen AE, Flø A, Russell K, Beitnes JO, Kløve SF, Hodt A, Gullestad L, Aukrust P, Gude E, Broch K, Ueland T.   +11 more
europepmc   +1 more source

Dipeptidyl peptidase-4 inhibitor linagliptin reduces inflammatory response, ameliorates tissue edema formation, and improves survival in severe sepsis

Denis Delić, Thomas Klein, Christian T. Wohnhaas, Huiying Feng, Xinchun Lin, Jin-Rui Zhang, Dongmei Wu   +6 more
openalex   +1 more source

DIPEPTIDYL PEPTIDASE-4 INHIBITORS: POTENTIAL FOR TREATMENT OF METABOLIC SYNDROME AND DEVELOPED FORMULATION APPROACHES

, 2017
Rakesh Mishra, Shashikant Dhole
openalex   +2 more sources

The dipeptidyl peptidase-4 inhibitor linagliptin ameliorates LPS-induced acute lung injury by maintenance of pulmonary microvascular barrier via activating the Epac1/AKT pathway

, 2022
Na Zhang, Sihui Tang, Jinjin Zhang, Biwei Pei, Tingting Pang, Gengyun Sun   +5 more
openalex   +1 more source

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes [PDF]

, 2016
Daisuke Koya, Keizo Kanasaki, Sen Shi
core   +1 more source

Sita‐ and saxagliptin use and autoantibodies to autoimmune bullous diseases: A cross‐sectional study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Sören Dräger, Claudia Kauderer, Svenja Meyhöfer, Leonie Dräger, Jens U. Marquardt, Ralf J. Ludwig, Stephan Arndt, Katharina Boch, Katja Bieber   +8 more
wiley   +1 more source

Associations of Diabetes, Smoking, and Metabolic Factors With the Risk of Breast and Prostate Cancers: A Population‐Based Retrospective Cohort Study

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Background Previous studies reported an inverse association between diabetes and prostate cancer. Moreover, the associations of smoking with breast and prostate cancers remain inconclusive. This study aims to investigate whether diabetes, smoking, or metabolic factors are associated with female breast and prostate cancers incidence, and ...
Sarah Tsz Yui Yau, Chi Tim Hung, Eman Yee Man Leung, Albert Lee, Eng Kiong Yeoh   +4 more
wiley   +1 more source

Dipeptidyl Peptidase 4 Inhibitor, an Update [PDF]

The Journal of Korean Diabetes, 2021
openaire   +1 more source